Skip to main content
. 2020 Dec 14;104:293–296. doi: 10.1016/j.ijid.2020.12.026

Table 1.

Baseline characteristics of HIV-positive patients with COVID-19 diagnosis.

N All Asymptomatic/mild COVID-19 Moderate/severe COVID-19 P value
N = 15 N = 19
Women, n (%) 34 10 (29.4) 3 (20.0) 7 (36.8) 0.451*
Age in years, median (IQR) 34 40.5 (36.0–48.0) 44.0 (32.0–47.0) 39.0 (36.0–51.0) 0.945**
BMI in kg/m2, median (IQR) (n = 27) 27 26.0 (23.0–27.0) 25.5 (23.5–28.5) 26 (22.5–27.0) 0.606**
Comorbidities, n (%) 34 18 (52.9) 6 (40.0) 12 (63.2) 0.489*
- Cardiovascular disease 5 2 3
- Chronic lung disease 2 1 1
- Diabetes 2 0 2
- Hypertension 2 0 2
- Other 7 3 4
HBV or HCV co-infection, n (%) 34 11 (32.3) 6 (40.0) 5 (26.3) 0.475*
Current drug user, n (%) 34 2 (5.9) 0 (0.0) 2 (10.5) 0.692*
Current smoker, n (%) 34 11 (32.3) 7 (46.7) 4 (21.0) 0.430*
Time since HIV diagnosis, median (IQR) 34 5.0 (1.0–14.0) 7.0 (2.0–14.0) 5.0 (1.0–14.0) 0.638**
Mode of HIV transmission, n (%): 34 0.249*
IDU 5 (14.7) 2 (13.3) 3 (15.8)
MSM 13 (38.2) 7 (46.7) 6 (31.6)
Heterosexual 14 (41.2) 4 (26.7) 10 (52.6)
Unknown 2 (5.9) 2 (13.3) 0 (0.0)
Nadir CD4+ count, median (IQR) 34 255.5 (88–381) 310 (224–429) 219 (61–318) 0.218**
Latest CD4+ count, median (IQR) 34 557 (312–708) 598 493–830 491 (204–683) 0.160**
Baseline HIV VL log copies/mL, median (IQR) (n = 31) 31 4.93 (4.20−6.00) 4.93 (3.97−5.98) 5.09 (4.23−6.00) 0.548**
Undetectable HIV VL before COVID-19, n (%) (n = 33) 33 18 (54.5) 8 (53.3) 10 (55.5) 1.000*
On cART, n (%) 34 28 (82.3) 13 (86.7) 15 (78.9) 0.672*
Protease inhibitor in regimen (any), n (%) 34 6 (17.6) 5 (33.3) 1 (5.3) 0.066*
  • -

    darunavir/cobicistat

 3 2 1 –
  • -

    lopinavir/ritonavir

 3 3 0 –
Integrase inhibitors regimen (any), n (%) 34 16 (47.0) 7 (46.7) 9 (47.4) 0.730*
  • -

    bictegravir

 1 0 1 –
  • -

    dolutegravir

 11 6 5 –
  • -

    elvitegravir/cobicistat

 3 1 2 –
  • -

    raltegravir

 1 0 1 –
Non-nucleoside reverse transcriptase inhibitors, n (%) 34 6 (17.6) 0 (0.0) 6 (31.6) 0.0239*
Tenofovir in regimen (any salt), n (%) 34 17 (50.0) 8 (53.3) 9 (47.4) 1.000*
  • -

    tenofovir alafenamide

 5 2 3 –
  • -

    tenofovir disoproxil

 12 6 6 –
Intensive Care Unit stay, n (%) 34 3 (8.8) 0 (0.0) 3 (15.8) 0.238*
Mechanical ventilation, n (%) 34 2 (5.9) 0 (0.0) 2 (5.3) 0.492*
COVID-19 specific treatment (any), n (%) 34 11 (32.3) 1 (6.7) 10 (52.6) 0.0083*
Outcome: 34 0.0187*
Died, n(%) 2 (5.9) 0 (0.0) 2 (10.5)
Fully recovered, n(%) 26 (76.5) 15 (100.0) 11 (57.9)
Still in hospital, n(%) 6 (17.6) 0 (0.0) 6 (31.6)

IQR – interquartile range, BMI – body mass index, HCV – hepatitis C virus, HBV – hepatitis B virus, COVID-19 – Coronavirus Disease 2019.

*

Fisher exact test.

**

Kruskal–Wallis test.